A real world study of the first bevacizumab biological analogue in China (Ankeda) in patients with Colorectal cancer field

ABSTRACT: Interventions: Case series:Nil Primary outcome(s): Objective Response Rate Study Design: Single arm

DISEASE(S): Colorectal Cancer

PROVIDER: 2700061 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR